Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF FINANCIAL OFFICER | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 20,854 |
Ending reported balance
After 2026-09-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 2,694 · Balance 18,848 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-09-01 · Exercise / conversion · Acquired 1,750 · Balance 20,598 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 1,591 · Balance 22,189 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 3,069 · Balance 25,258 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Tax withholding · Disposed 4,404 · Balance 20,854 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,800 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Grant · Acquired 7,800 · Balance 7,800 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 9,206 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Exercise / conversion · Disposed 3,069 · Balance 9,206 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,182 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Exercise / conversion · Disposed 1,591 · Balance 3,182 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 1,750 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 1,750 · Balance 1,750 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,694 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 31,150 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Grant · Acquired 31,150 · Balance 31,150 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 28, 2025 Filed Oct 30, 2025 20:47 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 100 | $41.00 | $4,100.00 |
DisclosureSEC source: 0001835458-25-000003 · form4-10302025_081002.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,086 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:47 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 100 | $30.93 | $3,093.00 |
DisclosureSEC source: 0001835458-25-000003 · form4-10302025_081002.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023553 · form4-09032025_080932.xml · derivative · entry 12 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 1,861 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 900 | $34.28 | $30,852.00 |
DisclosureSEC source: 0001415889-25-023553 · form4-09032025_080932.xml · nonDerivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,086 Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,861 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023553 · form4-09032025_080932.xml · nonDerivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023553 · form4-09032025_080932.xml · derivative · entry 11 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,694 Underlying: Class A Ordinary Share · 2,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023553 · form4-09032025_080932.xml · derivative · entry 10 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 Underlying: Class A Ordinary Share · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023553 · form4-09032025_080932.xml · derivative · entry 9 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,773 Underlying: Class A Ordinary Share · 1,592 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 39,363 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001415889-25-023553 · form4-09032025_080932.xml · derivative · entry 8 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,363 Underlying: Class A Ordinary Share · 39,363 shares Expires 2035-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 12,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023553 · form4-09032025_080932.xml · derivative · entry 7 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,275 Underlying: Class A Ordinary Share · 12,275 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 2,920 | $33.49 | $97,790.80 |
DisclosureSEC source: 0001415889-25-023553 · form4-09032025_080932.xml · nonDerivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,125 Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023553 · form4-09032025_080932.xml · nonDerivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023553 · form4-09032025_080932.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,592 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023553 · form4-09032025_080932.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 18,889 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001415889-25-021178 · form4-08062025_040802.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,036 Underlying: Class A Ordinary Share · 18,889 shares Expires 2031-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is March 16, 2021. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 18,889 | $32.89 | $621,259.21 |
DisclosureSEC source: 0001415889-25-021178 · form4-08062025_040802.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,009 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 18,889 | $22.89 | $432,369.21 |
DisclosureSEC source: 0001415889-25-021178 · form4-08062025_040802.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 18,299 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015778 · form4-06052025_080632.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 18,299 shares Expires 2028-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 18,299 | $28.80 | $527,011.20 |
DisclosureSEC source: 0001415889-25-015778 · form4-06052025_080632.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,009 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 18,299 | $18.00 | $329,382.00 |
DisclosureSEC source: 0001415889-25-015778 · form4-06052025_080632.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| May 01, 2025 Filed May 1, 2025 22:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 13,141 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0001415889-25-011690 · form4-05012025_100529.xml · derivative · entry 13 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,909 Underlying: Class A Ordinary Share · 13,141 shares Expires 2033-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. Read SEC document |
| May 01, 2025 Filed May 1, 2025 22:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 12,000 | $0.00 Strike: $17.92 | $0.00 |
DisclosureSEC source: 0001415889-25-011690 · form4-05012025_100529.xml · derivative · entry 12 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 12,000 shares Expires 2029-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 01, 2025 Filed May 1, 2025 22:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 25,141 | $27.80 | $698,919.80 |
DisclosureSEC source: 0001415889-25-011690 · form4-05012025_100529.xml · nonDerivative · entry 8 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,009 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| May 01, 2025 Filed May 1, 2025 22:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 13,141 | $17.76 | $233,384.16 |
DisclosureSEC source: 0001415889-25-011690 · form4-05012025_100529.xml · nonDerivative · entry 7 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| May 01, 2025 Filed May 1, 2025 22:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 12,000 | $17.92 | $215,040.00 |
DisclosureSEC source: 0001415889-25-011690 · form4-05012025_100529.xml · nonDerivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:50 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Option · Derivative | 7,606 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001415889-25-011981 · form4-05052025_080539.xml · derivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,606 Underlying: Class A Ordinary Share · 7,606 shares Expires 2035-04-30 F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F6 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:50 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Option · Derivative | 7,368 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001415889-25-011981 · form4-05052025_080539.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,368 Underlying: Class A Ordinary Share · 7,368 shares Expires 2035-04-30 F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F5 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:50 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 4,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011981 · form4-05052025_080539.xml · derivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,876 Underlying: Class A Ordinary Share · 4,786 shares Expires not disclosed F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F4 · derivative.exercise_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. F4 · derivative.expiration_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:50 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 4,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011981 · form4-05052025_080539.xml · derivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,558 Underlying: Class A Ordinary Share · 4,558 shares Expires not disclosed F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F3 · derivative.exercise_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. F3 · derivative.expiration_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| April 30, 2025 Filed May 1, 2025 22:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 21,254 | $0.00 Strike: $16.90 | $0.00 |
DisclosureSEC source: 0001415889-25-011690 · form4-05012025_100529.xml · derivative · entry 11 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,471 Underlying: Class A Ordinary Share · 21,254 shares Expires 2031-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 30, 2025 Filed May 1, 2025 22:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 21,254 | $26.95 | $572,795.30 |
DisclosureSEC source: 0001415889-25-011690 · form4-05012025_100529.xml · nonDerivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,009 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| April 30, 2025 Filed May 1, 2025 22:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 21,254 | $16.90 | $359,192.60 |
DisclosureSEC source: 0001415889-25-011690 · form4-05012025_100529.xml · nonDerivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 22,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001415889-25-011690 · form4-05012025_100529.xml · derivative · entry 10 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 22,000 shares Expires 2030-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 20,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001415889-25-011690 · form4-05012025_100529.xml · derivative · entry 9 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 20,000 shares Expires 2030-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 42,000 | $25.61 | $1,075,620.00 |
DisclosureSEC source: 0001415889-25-011690 · form4-05012025_100529.xml · nonDerivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,009 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $25.50 and $25.935. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 22,000 | $15.50 | $341,000.00 |
DisclosureSEC source: 0001415889-25-011690 · form4-05012025_100529.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 20,000 | $15.52 | $310,400.00 |
DisclosureSEC source: 0001415889-25-011690 · form4-05012025_100529.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| April 26, 2025 Filed Apr 29, 2025 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011502 · form4-04292025_080403.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021. Read SEC document |
| April 26, 2025 Filed Apr 29, 2025 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 479 | $21.37 | $10,233.84 |
DisclosureSEC source: 0001415889-25-011502 · form4-04292025_080403.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,009 Read SEC document |
| April 26, 2025 Filed Apr 29, 2025 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-011502 · form4-04292025_080403.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010485 · form4-04092025_080402.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,694 Underlying: Class A Ordinary Share · 2,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 1,303 | $20.28 | $26,424.84 |
DisclosureSEC source: 0001415889-25-010485 · form4-04092025_080402.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,498 Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010485 · form4-04092025_080402.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010004 · form4-04032025_090414.xml · derivative · entry 9 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,773 Underlying: Class A Ordinary Share · 1,592 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010004 · form4-04032025_090414.xml · derivative · entry 8 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 Underlying: Class A Ordinary Share · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 14,765 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010004 · form4-04032025_090414.xml · derivative · entry 7 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,765 Underlying: Class A Ordinary Share · 14,765 shares Expires not disclosed F4 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee F5 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply. F5 · derivative.expiration_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 7,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010004 · form4-04032025_090414.xml · derivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,382 Underlying: Class A Ordinary Share · 7,382 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 29,480 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001415889-25-010004 · form4-04032025_090414.xml · derivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,480 Underlying: Class A Ordinary Share · 29,480 shares Expires 2035-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 770 | $21.77 | $16,762.90 |
DisclosureSEC source: 0001415889-25-010004 · form4-04032025_090414.xml · nonDerivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,107 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 847 | $21.77 | $18,439.19 |
DisclosureSEC source: 0001415889-25-010004 · form4-04032025_090414.xml · nonDerivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,877 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.